Although the mechanism underlying how PCSK9 R93C is involved in reducing PMI risks remains elusive, there are several possible explanations: 1) The variant may directly delay the occurrence and development of atherosclerosis by reducing LDL-C levels; 2) PCSK9 participates in the onset and progression of atherosclerosis by promoting inflammation and macrophage apoptosis. This evidence concerns the gene PCSK9 and atherosclerosis.